Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.43 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 10/20 | 0.42 |
| ▸ | CSF1R | P07333 | 2/20 | 0.41 |
| ▸ | LCK | P06239 | 2/20 | 0.41 |
| ▸ | GAK | O14976 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1260737 | 0.85 | ENPP1 (0.54) | KDRENPP1EGFRCSF1RLCK | |
| SCHEMBL20051017 | 0.84 | PDE10A (0.43) | KDRENPP1EGFRLCKGAK | |
| SCHEMBL12779104 | 0.82 | KDR (0.48) | KDRENPP1EGFRCSF1RLCK | |
| SCHEMBL23501083 | 0.81 | ENPP1 (0.63) | KDRENPP1EGFRCSF1RLCK | |
| SCHEMBL23500791 | 0.81 | RET (0.43) | KDRENPP1EGFRLCKGAK | |
| SCHEMBL11315816 | 0.79 | EGFR (0.52) | KDREGFRLCKGAKRET | |
| SCHEMBL7861691 | 0.79 | LCK (0.44) | KDRENPP1EGFRCSF1RLCK | |
| SCHEMBL24393302 | 0.77 | ENPP1 (0.54) | KDRENPP1EGFRCSF1RLCK | |
| SCHEMBL24393297 | 0.77 | ENPP1 (0.70) | KDRENPP1EGFRCSF1RLCK | |
| SCHEMBL24009138 | 0.76 | EGFR (0.54) | KDRENPP1EGFRCSF1RSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099946-A1 | Quinazoline Derivatives as VEGF Inhibitors | GENZYME CORPORATION (US) | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099946-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT4, FLT1, KDR | KDR 3/4885ENPP1 3518/4885EGFR 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.